Table 4 Demographic characteristics and specific clinical information of patients with new onset uveitis following COVID-19 infection
Patient No. | Sex | Age | Time interval of onset (days) | Etiology | eye | History of uveitis-related systemic disease | History of ocular disease | Initial visit | Treatment | Follow-up time (months) | Final visit | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BCVA (Log-MAR) | IOP | Ocular examinations | BCVA (Log-MAR) | IOP | Ocular examinations | ||||||||||
1 | F | 57 | 26 | VKH | OU | - | Cataracts | 0.8/0.7 | 16.2/19.3 | OU: AC cells grade 2+; Dust-like KPs; VH grade 2+; Optic disc edema; ERD; Choroiditis | Steroid eye drops; Mydriatic eye drops; Oral prednisone | 6 | 0.1/0.1 | 15.7/16.4 | OU: AC cells grade 0; VH grade 0; Resolution of sub-retinal fluids |
2 | F | 49 | 42 | VKH | OU | - | - | 0.3/1.0 | 13.6/13.6 | OU: Optic disc edema ; ERD; Choroiditis | Oral prednisone | 1.5 | 0.2/0.4 | 14.9/13.0 | OU: Resolution of subretinal fluids |
3 | F | 76 | 30 | VKH | OU | - | Cataracts | 0.8/1.0 | 23.2/20.9 | OU: AC cells grade 3+; VH grade 1+; Optic disc edema; ERD; Choroiditis | Steroid eye drops; Mydriatic eye drops; Oral prednisone | 1 | 0.5/0.5 | 12.7/14.9 | OU: Resolution of subretinal fluids |
4 | M | 23 | 10 | VKH | OU | - | FS-LASIK Postoperative | 0.0/0.0 | 17.7/16.3 | OU: Optic disc edema; ERD; Choroidi-tis | Oral prednisone | 6.5 | 0.0/0.0 | 14.8/13.4 | OU: Resolution ofsubretinal fluids |
5 | F | 7 | 28 | JIA-related anterior uveitis | OS | JIA | - | 0.0 | 9.7 | OS: AC cells grade 2+; Mutton-fat KPs | Steroid eye drops; Mydriatic eye drops; | 2 | 0.0 | 11.8 | OS: AC cells grade 0 |
6 | F | 69 | 1 | Idiopathic anterior uveitis | OD | - | AMD | 1.3 | 16.4 | OD: AC cells grade 0.5+ | Steroid eye drops | 2 | 1.3 | 18.6 | OD: AC cells grade 0 |
7 | F | 58 | 20 | Idiopathic anterior uveitis | OS | - | - | 0.1 | 18.5 | OS: AC cells grade 2+; | Steroid eye drops; Mydriatic eye drops; | 2 | 0.0 | 19.8 | OS: AC cells grade 0 |
8 | M | 12 | 8 | pediatric intermedia-te uveitis | OU | - | - | 0.0/0.0 | 16.2/12.8 | OU: AC cells grade2+; VH grade 0.5+;Peripheral retinal capillary leakage | Steroid eye drops; Mydriatic eye drops; Oral methotrexate; ad-alimumab | 5 | 0.0/0.0 | 16.8/15.9 | OU: AC cells grade 0;VH grade 0 |
9 | F | 53 | 10 | Idiopathic posterior uveitis | OS | - | - | 0.0 | 17.5 | OS: VH grade 0.5+; Chorioretinitis | Oral prednisone | No follow-up visits | - | - | - |
10 | F | 56 | 20 | Idiopathic panuveitis | OS | - | Cataracts | 0.0 | 13.4 | OS: AC cells grade 1+; VH grade 0.5+; Chorioretinitis | Patient refused oral corticostero-ids; Steroid eye drops; Mydriatic eye drops; | 1.5 | 0.0 | 18.3 | OS: AC cells grade 0;VH grade 0.5+; Chorioretinitis |
11 | F | 60 | 3 | Idiopathic panuveitis | OD | - | - | 0.4 | 17.3 | OD: iris posterior synechia; VH grade 2+; diffuse retinal vasculitis; | Steroid eye drops; Mydriatic eye drops; Oral prednisone | 5 | 0.0 | 18.7 | OD: VH grade 0; Reduced retinal vascular leakage |
12 | F | 39 | 34 | Idiopathic panuveitis | OS | - | - | 0.4 | 9.6 | OS: AC cells grade 3+; VH grade 2+; Chorioretinitis | Steroid eye drops; Mydriatic eye drops; Oral prednisone; Oral azathioprine | 6 | 0.0 | 13.2 | OS: AC cells grade 0;VH grade 0 |
13 | F | 13 | 7 | pediatric panuveitis | OU | - | OS: Amblyopia | 0.1/0.7 | 11.1/10.5 | OD: AC cells grade2+; VH grade 3+. OS: AC cells grade1+; VH grade 2+. OU: Mutton-fat KPs; iris posterior synechia; CME | Steroid eye drops; Mydriatic eye drops; Oral prednisone; Oral methotrexate | No follow-up visits | - | - | - |